Hikma Executive Vice Chairman Buys £1.5m of Company Shares

Hikma Pharmaceuticals ( (GB:HIK) ) has issued an update.

Hikma Pharmaceuticals has disclosed that Executive Vice Chairman Mazen Darwazah purchased 100,000 ordinary shares in the company on 19 December 2025 on the London Stock Exchange, at a price of £14.986 per share, for a total consideration of approximately £1.5 million. The insider share purchase, reported under EU-market abuse regulations, may be interpreted by investors as a signal of confidence from senior leadership in Hikma’s prospects and valuation, potentially supporting market sentiment around the stock.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1793.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on GB:HIK Stock

According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.

Hikma Pharmaceuticals’ overall stock score is driven by strong financial performance and attractive valuation. While technical indicators suggest a bearish trend, the company’s strategic achievements and executive confidence provide a positive outlook. Earnings call insights and corporate events further support the stock’s potential for growth.

To see Spark’s full report on GB:HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals is a London-listed multinational pharmaceutical company that develops, manufactures and markets a broad range of generic and branded medicines, with a particular focus on injectable and oral treatments for global markets. The group operates across the US, Europe, the Middle East and North Africa, supplying hospitals and healthcare systems with essential medicines.

Average Trading Volume: 743,709

Technical Sentiment Signal: Sell

Current Market Cap: £3.34B

For a thorough assessment of HIK stock, go to TipRanks’ Stock Analysis page.